| Leukemia, Myelocytic, Acute
Nivestym vs Vanflyta
Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.Deep comparison between: Nivestym vs Vanflyta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVanflyta has a higher rate of injection site reactions vs Nivestym based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vanflyta but not Nivestym, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nivestym
Vanflyta
At A Glance
SC injection or IV infusion
Daily
G-CSF analog
Oral
Once daily
FLT3 inhibitor
Indications
- Leukemia, Myelocytic, Acute
- Severe congenital neutropenia
- Cyclic neutropenia
- Idiopathic neutropenia
- Leukemia, Myelocytic, Acute
Dosing
Cancer receiving myelosuppressive chemotherapy, Leukemia, Myelocytic, Acute 5 mcg/kg/day SC injection, short IV infusion (15-30 min), or continuous IV infusion; administer at least 24 hours after cytotoxic chemotherapy; continue daily for up to 2 weeks or until ANC reaches 10,000/mm3 after the expected nadir.
Cancer undergoing bone marrow transplantation 10 mcg/kg/day IV infusion no longer than 24 hours; administer first dose at least 24 hours after cytotoxic chemotherapy and at least 24 hours after bone marrow infusion; titrate against neutrophil response per dosage adjustment table.
Autologous peripheral blood progenitor cell mobilization 10 mcg/kg/day SC injection; administer at least 4 days before first leukapheresis and continue until last leukapheresis; discontinue if WBC rises above 100,000/mm3.
Severe congenital neutropenia 6 mcg/kg SC injection twice daily; individualize based on clinical course and ANC with chronic daily administration.
Cyclic neutropenia, Idiopathic neutropenia 5 mcg/kg SC injection once daily; individualize based on clinical course and ANC with chronic daily administration.
Leukemia, Myelocytic, Acute Induction: 35.4 mg orally once daily on Days 8 to 21 of each 28-day cycle, up to 2 cycles with cytarabine and anthracycline; Consolidation: 35.4 mg once daily on Days 6 to 19 of each cycle, up to 4 cycles with high-dose cytarabine; Maintenance: 26.5 mg once daily (escalate to 53 mg on Day 15 if QTcF <=450 ms), continuous once-daily with no break for up to 36 cycles.
Contraindications
- History of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products
- Severe hypokalemia
- Severe hypomagnesemia
- Long QT syndrome
- History of ventricular arrhythmias or torsades de pointes
Adverse Reactions
Most common (>=5% higher incidence vs placebo) Pyrexia, nausea, fatigue, thrombocytopenia, back pain, bone pain, rash, dizziness, dyspnea, cough, chest pain, arthralgia, pain in extremity, increased blood alkaline phosphatase, increased blood lactate dehydrogenase
Serious Splenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle cell disorders, glomerulonephritis, alveolar hemorrhage and hemoptysis, capillary leak syndrome, myelodysplastic syndrome, acute myeloid leukemia, thrombocytopenia, leukocytosis, cutaneous vasculitis, aortitis
Postmarketing Anaphylaxis, splenomegaly, Sweet's syndrome, decreased bone density and osteoporosis (pediatric chronic use), extramedullary hematopoiesis
Most common (>=10%) Febrile neutropenia, diarrhea, mucositis, nausea, sepsis, abdominal pain, vomiting, neutropenia, headache, upper respiratory tract infection, hypertransaminasemia, thrombocytopenia, fungal infection, herpesvirus infection, decreased appetite, epistaxis, insomnia, electrocardiogram QT prolonged, anemia, dyspepsia, eye irritation.
Serious Febrile neutropenia, sepsis, fungal infections, brain edema, pneumonia, cerebral infarction, acute respiratory distress syndrome, pulmonary embolism, ventricular dysfunction, cardiac arrest.
Pharmacology
Filgrastim-aafi is a recombinant G-CSF analog that binds to specific cell surface receptors on hematopoietic cells, stimulating neutrophil progenitor proliferation, differentiation, and end-cell functional activation; its activity is selective for the neutrophil lineage with minimal effects on other hematopoietic cell types.
Quizartinib is a small molecule inhibitor of the receptor tyrosine kinase FLT3; it and its active metabolite AC886 bind the ATP binding domain of FLT3, inhibiting kinase activity and downstream FLT3 receptor signaling, thereby blocking FLT3-ITD-dependent cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nivestym
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (7/12) · Qty limit (0/12)
Vanflyta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Nivestym
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vanflyta
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Nivestym
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (1/3)
Vanflyta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NivestymView full Nivestym profile
VanflytaView full Vanflyta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.